FIELD: medicine. SUBSTANCE: method involves determining contents of autoantibodies to quiscavalate-binding membrane protein in patient blood in addition to electroencephalographic monitoring. The measurements are performed by means of paroxysmal activity test before pharmacotherapy and every 15-20 days in dynamic mode. Contents of autoantibodies to quiscavalate-binding membrane protein being reduced at least by 10 conditional units in every following test, the pharmacotherapy is considered as effective one. EFFECT: increased objectivity of evaluation. 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSTICS AND PREDICTION OF EPILEPSY DEVELOPMENT IN PATIENTS AT PRECLINICAL STAGE OF THE DISEASE | 2001 |
|
RU2188575C1 |
| METHOD OF THERAPY IN PATIENTS WITH PHARMACOTHERAPY- RESISTANT EPILEPSY FORMS | 2000 |
|
RU2178298C1 |
| METHOD FOR PREDICTING PRE-CLINICAL STAGE OF EPILEPSY | 2003 |
|
RU2246727C2 |
| METHOD FOR PREDICTING REMISSION OF EPILEPSY | 2003 |
|
RU2238029C1 |
| METHOD OF DIAGNOSING AND TREATING PRECLINICAL EPILEPSY PHASE | 2003 |
|
RU2231363C1 |
| METHOD FOR DIAGNOSING THE CASES OF EPILEPSY AND ITS PRELIMINARY STAGE | 1999 |
|
RU2156607C1 |
| METHOD FOR COMPLEX THERAPY OF EPILEPSY IN TEENAGERS | 2002 |
|
RU2238035C2 |
| METHOD FOR PREDICTING AND TREATING IDIOPATHIC GENERALIZED EPILEPSY IN CHILDREN | 2005 |
|
RU2297176C2 |
| METHOD OF ESTIMATING SEVERITY DEGREE OF EPILEPSY COMPLICATED BY ORGANIC ENCELOPHATHY | 2009 |
|
RU2433784C2 |
| METHOD FOR DIAGNOSING AND PREDICTING EPILEPSY DEVELOPMENT IN PATIENTS AT PRECLINICAL DISEASE STAGE | 2001 |
|
RU2189776C1 |
